Cargando…

The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis

BACKGROUND: While adjuvant chemotherapy benefits patients with pancreatic ductal adenocarcinoma (PDAC), the importance of the time to initiation of adjuvant therapy remains unclear. AIM: This study seeks to better understand whether the timing of postoperative chemotherapy initiation affects long‐te...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugumar, Kavin, Hue, Jonathan J., De La Serna, Solanus, Rothermel, Luke D., Ocuin, Lee M., Hardacre, Jeffrey M., Ammori, John B., Winter, Jordan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552002/
https://www.ncbi.nlm.nih.gov/pubmed/34245139
http://dx.doi.org/10.1002/cnr2.1390
_version_ 1784591289266733056
author Sugumar, Kavin
Hue, Jonathan J.
De La Serna, Solanus
Rothermel, Luke D.
Ocuin, Lee M.
Hardacre, Jeffrey M.
Ammori, John B.
Winter, Jordan M.
author_facet Sugumar, Kavin
Hue, Jonathan J.
De La Serna, Solanus
Rothermel, Luke D.
Ocuin, Lee M.
Hardacre, Jeffrey M.
Ammori, John B.
Winter, Jordan M.
author_sort Sugumar, Kavin
collection PubMed
description BACKGROUND: While adjuvant chemotherapy benefits patients with pancreatic ductal adenocarcinoma (PDAC), the importance of the time to initiation of adjuvant therapy remains unclear. AIM: This study seeks to better understand whether the timing of postoperative chemotherapy initiation affects long‐term outcomes in PDAC. METHODS AND RESULTS: A systematic literature search was performed in Medline, Embase, and Cochrane Library in March 2020. Studies focused on the association between the timing of adjuvant therapy on long‐term outcomes in resected PDAC patients were included. The impact of early and delayed therapy as defined by the respective studies was evaluated using forest plot analysis. Overall survival (OS) and disease‐free survival (DFS) served as primary endpoints. Out of 3099 published articles, 10 retrospective studies met inclusion criteria. Combined, these studies included clinical data of 13 344 patients. The cut off used to define “early” and “delayed” treatment groups varied in the included studies ranging from 3 to 12 weeks. Due to this heterogeneity, a sub‐group analysis of three time cut offs was performed: 3 to 5 weeks, 6 to 8 weeks, and 9 to 12 weeks. There was a significant decrease in OS and DFS when adjuvant therapy was delayed by 3 to 5 weeks after surgery (OS, pooled hazard ratio [HR] = 1.86, 95% confidence interval [CI] = 1.25‐2.78; DFS, pooled HR = 1.62, 95% CI = 1.12‐2.34). However, due to small sample size and limited studies in this subgroup analysis, the results may be indeterminate. There was no significant decrease in OS with delayed initiation of adjuvant therapy by 6 to 8 weeks and 9 to 12 weeks. Similarly, delay in adjuvant therapy beyond 3‐5 weeks. CONCLUSIONS: There was no conclusive evidence suggesting improved survival in patients starting treatment at various time cut offs. Studies investigating the extreme ends of the time‐to‐treatment spectrum may prove more informative.
format Online
Article
Text
id pubmed-8552002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85520022021-11-04 The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis Sugumar, Kavin Hue, Jonathan J. De La Serna, Solanus Rothermel, Luke D. Ocuin, Lee M. Hardacre, Jeffrey M. Ammori, John B. Winter, Jordan M. Cancer Rep (Hoboken) Original Articles BACKGROUND: While adjuvant chemotherapy benefits patients with pancreatic ductal adenocarcinoma (PDAC), the importance of the time to initiation of adjuvant therapy remains unclear. AIM: This study seeks to better understand whether the timing of postoperative chemotherapy initiation affects long‐term outcomes in PDAC. METHODS AND RESULTS: A systematic literature search was performed in Medline, Embase, and Cochrane Library in March 2020. Studies focused on the association between the timing of adjuvant therapy on long‐term outcomes in resected PDAC patients were included. The impact of early and delayed therapy as defined by the respective studies was evaluated using forest plot analysis. Overall survival (OS) and disease‐free survival (DFS) served as primary endpoints. Out of 3099 published articles, 10 retrospective studies met inclusion criteria. Combined, these studies included clinical data of 13 344 patients. The cut off used to define “early” and “delayed” treatment groups varied in the included studies ranging from 3 to 12 weeks. Due to this heterogeneity, a sub‐group analysis of three time cut offs was performed: 3 to 5 weeks, 6 to 8 weeks, and 9 to 12 weeks. There was a significant decrease in OS and DFS when adjuvant therapy was delayed by 3 to 5 weeks after surgery (OS, pooled hazard ratio [HR] = 1.86, 95% confidence interval [CI] = 1.25‐2.78; DFS, pooled HR = 1.62, 95% CI = 1.12‐2.34). However, due to small sample size and limited studies in this subgroup analysis, the results may be indeterminate. There was no significant decrease in OS with delayed initiation of adjuvant therapy by 6 to 8 weeks and 9 to 12 weeks. Similarly, delay in adjuvant therapy beyond 3‐5 weeks. CONCLUSIONS: There was no conclusive evidence suggesting improved survival in patients starting treatment at various time cut offs. Studies investigating the extreme ends of the time‐to‐treatment spectrum may prove more informative. John Wiley and Sons Inc. 2021-07-10 /pmc/articles/PMC8552002/ /pubmed/34245139 http://dx.doi.org/10.1002/cnr2.1390 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Sugumar, Kavin
Hue, Jonathan J.
De La Serna, Solanus
Rothermel, Luke D.
Ocuin, Lee M.
Hardacre, Jeffrey M.
Ammori, John B.
Winter, Jordan M.
The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
title The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
title_full The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
title_fullStr The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
title_full_unstemmed The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
title_short The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
title_sort importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: a systematic review and meta‐analysis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552002/
https://www.ncbi.nlm.nih.gov/pubmed/34245139
http://dx.doi.org/10.1002/cnr2.1390
work_keys_str_mv AT sugumarkavin theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT huejonathanj theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT delasernasolanus theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT rothermelluked theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT ocuinleem theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT hardacrejeffreym theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT ammorijohnb theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT winterjordanm theimportanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT sugumarkavin importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT huejonathanj importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT delasernasolanus importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT rothermelluked importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT ocuinleem importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT hardacrejeffreym importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT ammorijohnb importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis
AT winterjordanm importanceoftimetoadjuvanttreatmentonsurvivalwithpancreaticcancerasystematicreviewandmetaanalysis